Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + 5-fluorouracil + folic acid
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a multi-agent chemotherapy regimen combining four agents: - **Paclitaxel** (PTX): a microtubule-stabilizing agent that inhibits cell division by promoting tubulin polymerization and preventing depolymerization. - **Cisplatin** (CDDP): a platinum-based compound that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **5-Fluorouracil** (5-FU): an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and function. - **Folic acid** (FA; often used as folinic acid/leucovorin in regimens): enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxicity. This combination is designed for synergistic antitumor activity. It has been studied for use in various solid tumors including metastatic breast cancer and other cancers overexpressing folate receptors. Folic acid may also be used as a targeting ligand or modulator to enhance drug delivery or efficacy[1][2][4][7].
- Other names
- PTX + CDDP + 5-FU + FApaclitaxel/cisplatin/5-fluorouracil/folic acid combination
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))DNAFOLR1 (FRα)
Beyond the preview
Go deeper on paclitaxel + cisplatin + 5-fluorouracil + folic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + 5-fluorouracil + folic acid.